Palabras clave
Cómo citar
Resumen
El cáncer de mama (CM) es el cáncer más frecuente en la mujer en Argentina. Se estima una incidencia de 22.000 nuevos casos anuales. El CM en mujeres jóvenes (menores de 40 años) representa entre el 5-7% del total. El 70% de los CM son esporádicos, solo un 5-10% presentan una mutación genética. Presentaremos un caso clínico de una paciente joven con cáncer de mama y mutación genética asociada.
Citas
World Health Organization, Globocan, The Global Cancer Observatory, 2021.
Cardoso F, Loibl S, Pagani O,et al,The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012 Dec;48(18):3355-77
Sociedad Argentina de Mastología, Alto riesgo para cáncer de mama consenso nacional inter-sociedades, Revista Argentina de Radiología, 2017, 81(1): 62-87.
Cruzado J, La toma de decisión de los participantes en consejo genético oncológico, Psicooncologia, 2010;2-3 (7): 341-362
NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, 2023.
ACOG Clinical Management Guidelines for Obstetrician–Gynecologists, Hereditary breast and ovarian cancer syndrome, 2017.
Syed Y, Oncotype DX Breast Recurrence Score ® : A Review of its Use in Early-Stage Breast Cancer, Mol Diagn Ther. 2020; 24: 621–63
ESMO Clinical Practice Guidelines, Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients, 2023.
Oktay K, Turan V, Bedoschi G, et al, Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer, J Clin Oncol. 2015; 33: 2424-2429
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-784.
Draganescu M, Carmocan C. Hormone Therapy in Breast Cancer. Chirurgia, 2017 ;112(4):413-417.
Azar M, Hormonoterapia extendida. De la teoría a la práctica, Revista Argentina de Mastología, 2016; 129 (36): 7-9
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials, Lancet. 2015; 386: 1341-1352
Francis P , Pagani O , Fleming G, et al,Tailoring adjuvant endocrine therapy for premenopausal breast cancer, N Engl J Med 2018; 379:122-137
Partridge A, Niman S, Ruggeri M ,et al, Interrupting endocrine therapy to attempt pregnancy after breast cancer, N Engl J Med 2023; 388:1645-1656.